MGMT and central nervous system cancer: To determine the clinical predictive value of EMP3 expression, we incorporated factors, including age, sex, WHO grade, expression of Ki67 and PHH3, mutant status of P53, IDH1, and ATRX, methylation level of MGMT, and especially, EMP3 levels of 1013 glioma patients, into the Cox regression model.